Loading...

NGNE NEUROGENE INC US FDA Inspections 8-K Filing

NRGN

NGN

NEUROGENE INC

(NGNE)

2025 8-K

Dosing Completion

Annual Meeting Results

Quarterly Results Released

Board Expansion

Financial Results Announced

Breakthrough Designation

Corporate Updates Announcement

Quarterly Results Update

Positive Trial Results

Patient Dosing Initiated

FDA Protocol Update

Registrar Trials

Amendments to Plans

Other Special Situation

Financial Statements

Management Agreement

Financial Results

Corporate Update

Clinical Trial Update

Financial Results

Clinical Trial Update

Private Placement

Earnings Reports

Regulatory Approval

Regulation FD Disclosure

Annual Meeting of Stockholders

Regulation FD Disclosure

Earnings Reports

Gene Therapy Clinical Trial...

Departure of Directors or C...

Departure of Directors or C...

Earnings Reports

Regulation FD Disclosure

Appointment of Senior Vice ...

Press Release and Corporate...

Merger and Name Change

Merger Supplemental Disclos...

Revised CVR Agreement

Reverse Stock Split

Merger of Equals

Annual Meeting of Stockholders

Appointment of Officers

Restructuring and CEO Resig...

Strategic Review Announcement

External Links:

On October 9, 2025, Neurogene Inc. announced completion of discussions with the FDA regarding its trial protocol and plans to begin dosing participants in a registrational trial for Rett syndrome by the fourth quarter of 2025. They also presented data at the ESGCT Annual Congress highlighting that ICV administration is superior to IT-L for key brain region access.

AI Assistant

NEUROGENE INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.